Delivery Order SPE2DB25D9365-SPE2DB25FUJML

Award Date 2/19/25
Potential Completion Date 3/12/25
Potential Value $5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $6,312.30 contract is for the delivery of 130 mg/26 ml vials of the biologic drug Stelara, with a period of performance through February 25, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $7,574.76 contract is for the delivery of 130 mg/26 mL vials of the biologic medication Stelara. This delivery order is issued under DMS Pharmaceutical Group's $499,999,999 Indefinite Delivery Contract (IDC) with the DLA, which provides a broad range of pharmaceutical products and...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $7,461.12, is for the supply of Stelara 130 mg/26 ml vials. The order falls under DMS Pharmaceutical Group's $499,999,999 Indefinite Delivery Contract (IDC) with the DLA, which allows the agency to issue delivery orders for a comprehensive range of branded and generic...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $3,730.56 to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The contract is for the delivery of Stelara 130mg/26ml pharmaceutical product, with a performance period through December 13, 2024. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue firm...
This is a firm fixed-price delivery order worth $3,499.08 awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the provision of 4564390391 - STELARA 45 MG/0.5 ML SYRINGE 0.5ML, a specialized pharmaceutical product, with a period of performance through April 2024. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of a specialized pharmaceutical product, Stelara (130 mg/26 ml vial), with a ceiling value of $12,435.20 and an ultimate completion date of January 10, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $7,461.12 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of 4,566,373,759 units of the pharmaceutical drug STELARA 130 MG/26 ML VIAL 26ML, with a completion date of November 20, 2024. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables...
This federal contract award was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,974.08 firm fixed-price delivery order is for the pharmaceutical product Stelara 130 mg/26 ml vial, with a period of performance through December 30, 2024. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $7,461.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of 4564977234 - STELARA 130 MG/26 ML VIAL 26ML, and has a completion date of July 12, 2024. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA, valued at up to...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $14,922.24, is for the delivery of one pharmaceutical product, STELARA 130 MG/26 ML VIAL 26ML, with a period of performance through July 22, 2024. The contract is not set aside and is part of a larger indefinite delivery contract (IDC) valued up to $499,999,999 that DMS Pharmaceutical...
  • SPE2DB25D9365
    Indefinite Delivery Contract
  • SPE2DB25D9365-SPE2DB25FUJML
    Delivery Order

This is a firm fixed-price delivery order for $5,049.84 awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of 130 mg/26 ml vials of the biologic medication Stelara, with a period of performance through March 12, 2025.

DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. This specific award is not associated with a set-aside designation, allowing DMS Pharmaceutical Group to leverage its woman-owned small business status to secure direct federal contracts across multiple product categories.

Generated 5/21/25, 9:45 AM